Sweden's Qlife Q2 revenue rises on pharma project
Sweden's Qlife Q2 revenue rises on pharma project
Overview
Sweden diagnostics platform's Q2 revenue rose sharply, driven by pharma feasibility study
Company's Q2 EBITDA loss narrowed year-over-year
Company advanced partnerships and regulatory progress on Egoo Health platform
Outlook
Company aims to complete ongoing pharmaceutical feasibility project and explore next-stage collaboration
Qlife plans to broaden range of tests available on Egoo platform and expand pharmaceutical partnerships
Company continues progress toward IVDR certification of Egoo PHE in second half of 2026
Result Drivers
PHARMA FEASIBILITY STUDY - Q2 revenue was driven by a fully funded feasibility project with a global pharmaceutical company
PARTNERSHIP INITIATIVES - Co said ongoing strategic partnerships in pharmaceutical and diagnostics sectors contributed to business progress
DIAGNOSTIC PLATFORM EXPANSION - Validation activities and collaborations aimed at expanding Egoo platform test menu supported progress
Company press release: ID:nWkr2Qyqvh
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue |
| SEK 728,000 |
|
Q2 Adjusted Loss Per Share |
| SEK 0.17 |
|
Q2 EBITDA |
| -SEK 4.72 mln |
|
Reuters Recommended Reads
Aug 26 - Sweden's AlzeCure Pharma Q2 net sales surge on licensing deals
Aug 26 - Sweden's BioArctic Q2 revenue falls despite higher Leqembi royalties
Aug 24 - Sweden's Episurf posts H1 loss on goodwill impairment after property expansion
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)